VIRUSINIO HEPATITO DELTA INFEKCIJOS GYDYMAS

• 收藏
• 分享

专利权人:

Eiger Biopharmaceuticals; Inc.

发明人:

CORY, David,CHOONG, Ingrid,GLENN, Jeffrey

申请号：

LT15785846

公开号：

LT3137078T

申请日:

2015.05.01

申请国别(地区):

LT

年份:

2019

代理人:

摘要：

The prenyltransferase inhibitor lonafarnib and the CYP3A4 inhibitor ritonavir are used in combination to treat hepatitis delta virus (HDV) infection. HDV infection is treated by orally administering to the patient a therapeutically effective amount of lonafarnib and a therapeutically effective amount of a CYP3A4 inhibitor for at least 30 days. Optionally the treatment includes prophylactic administration of one or more GI modifying agents.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/